论文部分内容阅读
目的探讨西格列汀联合格列喹酮治疗2型糖尿病的临床效果。方法 80例门诊及住院初诊为2型糖尿病患者,随机分为A组和B组,各40例。A组给予西格列汀方案,B组给予西格列汀+格列喹酮。比较治疗前后两组患者血糖浓度、临床疗效及药物不良反应。结果 A组治疗后,患者空腹血糖(FPG)为(7.6±2.2)mmol/l、餐后2 h血糖(2 h PG)为(8.0±1.7)mmol/l、糖化血红蛋白(Hb A1c)为(7.5±1.6)%;B组患者FPG为(6.5±2.6)mmol/l、2 h PG为(7.3±1.4)mmol/l、Hb A1c为(6.2±1.5)%;两组治疗后比较,差异均有统计学意义(P<0.01)。两组患者未见低血糖发生。结论西格列汀联合格列喹酮能有效控制2型糖尿病患者血糖,且安全性良好,具有很好的临床推广价值。
Objective To investigate the clinical effect of sitagliptin and gliquidone in the treatment of type 2 diabetes mellitus. Methods 80 cases of outpatients and inpatients with newly diagnosed type 2 diabetes were randomly divided into A group and B group, 40 cases each. Group A received sitagliptin and group B received sitagliptin and gliquidone. Blood glucose levels, clinical efficacy and adverse drug reactions in two groups before and after treatment were compared. Results After treatment, the fasting blood glucose (FPG) was (7.6 ± 2.2) mmol / l, the postprandial 2 h PG was (8.0 ± 1.7) mmol / l and the Hb A1c was 7.5 ± 1.6)%. The FPG in group B was (6.5 ± 2.6) mmol / l, the duration of 2 h PG was (7.3 ± 1.4) mmol / l and the level of Hb A1c was (6.2 ± 1.5)%. All were statistically significant (P <0.01). No hypoglycemia occurred in both groups. Conclusion Sitagliptin combined with gliquidone can effectively control the blood sugar in patients with type 2 diabetes mellitus, and is safe and has good clinical value.